TY - JOUR
T1 - Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
T2 - Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells (Molecular Therapy (2018) 26(4) (963–975), (S1525001618300273), (10.1016/j.ymthe.2018.01.020))
AU - Xiong, Wei
AU - Chen, Yuhui
AU - Kang, Xi
AU - Chen, Zhiying
AU - Zheng, Peilin
AU - Hsu, Yi Hsin
AU - Jang, Joon Hee
AU - Qin, Lidong
AU - Liu, Hao
AU - Dotti, Gianpietro
AU - Liu, Dongfang
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2021/3/3
Y1 - 2021/3/3
N2 - (Molecular Therapy 26, 963–975; February 1, 2018) In the originally published version of this article, the DIC images in the Kappa-CAR-41BB panel (bottom) of Figure 2A were uploaded incorrectly, although we had repeated group data in Supplemental Figures 3A and 4A. The correct differential interference contrast (DIC) images are aligned with the images from the other three corresponding fluorescence channels. In the originally published right panel of Figure 3A, the specific lysis of CD19-CAR T cells was uploaded incorrectly and used the same graph as the Kappa-CAR group (left panel), although we had additional two-donor repeat group data in Supplemental Figure S5. The correct version is shown below. With regard to Figures 4B and 4C in the original article, the graphs from each condition were generated from different data, although the curve of the truncated membrane (TM) group looks very similar. We apologize that we repeated uploading the data of the same donor with donor #2 in Figure S7. The data of an additional three donors was included in Figure S7 to support the point that 4-1BB -CAR T cells have enhanced antitumor activity in the long-time killing assays. The correct version of the graph in Figure 4C is included below. We also removed the data of donor #2 from the original Figure S7. The main conclusion that the concept that “CAR immunological synapse quality can predict the efficacy of CAR-modified immune cells” from the original article has not been affected. Each co-first author can successfully repeat the other co-first author's key experiments. These factors could play a role in these careless errors during the manuscript preparation. However, the data are reliable, traceable, and repeatable, and the continuation of the project is still in progress. The authors regret these errors.
AB - (Molecular Therapy 26, 963–975; February 1, 2018) In the originally published version of this article, the DIC images in the Kappa-CAR-41BB panel (bottom) of Figure 2A were uploaded incorrectly, although we had repeated group data in Supplemental Figures 3A and 4A. The correct differential interference contrast (DIC) images are aligned with the images from the other three corresponding fluorescence channels. In the originally published right panel of Figure 3A, the specific lysis of CD19-CAR T cells was uploaded incorrectly and used the same graph as the Kappa-CAR group (left panel), although we had additional two-donor repeat group data in Supplemental Figure S5. The correct version is shown below. With regard to Figures 4B and 4C in the original article, the graphs from each condition were generated from different data, although the curve of the truncated membrane (TM) group looks very similar. We apologize that we repeated uploading the data of the same donor with donor #2 in Figure S7. The data of an additional three donors was included in Figure S7 to support the point that 4-1BB -CAR T cells have enhanced antitumor activity in the long-time killing assays. The correct version of the graph in Figure 4C is included below. We also removed the data of donor #2 from the original Figure S7. The main conclusion that the concept that “CAR immunological synapse quality can predict the efficacy of CAR-modified immune cells” from the original article has not been affected. Each co-first author can successfully repeat the other co-first author's key experiments. These factors could play a role in these careless errors during the manuscript preparation. However, the data are reliable, traceable, and repeatable, and the continuation of the project is still in progress. The authors regret these errors.
UR - http://www.scopus.com/inward/record.url?scp=85101001377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101001377&partnerID=8YFLogxK
U2 - 10.1016/j.ymthe.2021.01.025
DO - 10.1016/j.ymthe.2021.01.025
M3 - Article
C2 - 33592166
AN - SCOPUS:85101001377
SN - 1525-0016
VL - 29
SP - 1349
EP - 1351
JO - Molecular Therapy
JF - Molecular Therapy
IS - 3
ER -